The expert group HART (Health Advisory and Recovery Team) has delved into the Pfizer trial documents released following a U.S. court order and discovered that according to Pfizer’s own antibody data the vaccine efficacy in the trial was massively overstated and appears to be as low as zero.
While the official results found only eight PCR-positive ‘cases’ in the vaccine arm, Pfizer’s antibody testing shows that in fact 75 people in the vaccinated arm seroconverted (developed N-type antibodies), implying there were actually 75 ‘cases’ of Covid in the vaccinated, not just eight.
By itself that would cut efficacy in half. However, HART points out that it’s been shown with the Moderna mRNA vaccine that only around 40% of the vaccinated who go on to have a symptomatic PCR-positive Covid ‘breakthrough’ infection develop N-type antibodies, owing to immune imprinting (‘original antigenic sin’) by the vaccine to favour S-type antibodies (which target the spike protein). Assuming this also applies to the Pfizer mRNA vaccine, this means the 75 seropositive individuals are only around 40% of the total number who had Covid, giving an estimated total of 188 Covid ‘cases’ in the vaccine arm – more than the 165 in the unvaccinated arm, implying zero vaccine efficacy or worse.
How did Pfizer get away with claiming there were only eight Covid cases in the vaccinated arm? Mainly by excluding PCR-positives in the jabbed until seven days after the second dose. The problem with this is that, since Covid waves tend to infect only 10-20% of a population, evidently not everyone is equally susceptible to the virus. This means if those most susceptible to the virus in the vaccine arm catch it in the weeks before they are ‘fully vaccinated’ and so don’t count towards the vaccine arm ‘cases’, those remaining in the vaccine arm of the trial will be primarily those who are less susceptible to the virus, and so the trial will suffer from survivor bias, exaggerating efficacy.
Worth reading in full.